Targeting the p53-p21 axis in liver cancer: Linking cellular senescence to tumor suppression and progression

• Published in: Pathology, research and practice Vol. 263; p. 155652
• Main Authors: Thangavelu, Lakshmi, Altamimi, Abdulmalik S.A., Ghaboura, Nehmat, Babu, M. Arockia, Roopashree, R., Sharma, Pawan, Pal, Pusparghya, Choudhary, Chhavi, Prasad, G.V. Siva, Sinha, Aashna, Balaraman, Ashok Kumar, Rawat, Sushama
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.11.2024
• Subjects: Cellular senescence; Hepatocellular carcinoma; Liver cancer; P53-p21 pathway; Tumorigenesis; Liver cancer; Hepatocellular carcinoma; Tumorigenesis; P53-p21 pathway; Cellular senescence
• ISSN: 0344-0338; 1618-0631; 1618-0631
• DOI: 10.1016/j.prp.2024.155652

Liver cancer is a major health epidemic worldwide, mainly due to its high mortality rates and limited treatment options. The association of cellular senescence to tumorigenesis and the cancer hallmarks remains a subject of interest in cancer biology. The p53-p21 signalling axis is an important regulator in restoring the cell’s balance by supporting tumor suppression and tumorigenesis in liver cancer. We review the novel molecular mechanisms that p53 and its downstream effector, p21, employ to induce cellular senescence, making it last longer, and halt the proliferation of damaged hepatocytes to become tumorous cells. We also examine how dysregulation of this pathway contributes to HCC pathogenesis, proliferation, survival, acquired resistance to apoptosis, and increased invasiveness. Furthermore, we comprehensively describe the molecular cross-talk between the p53-p21 signalling axis and major cell cycle signalling pathways, including Wnt/β-catenin, PI3K/Akt, and TGF-β in liver cancer and provide an overview of promising candidates for chemoprevention and future therapeutic strategies. This review article explores the roles of the p53-p21 pathway in liver cancer, examining its function in promoting cellular senescence under normal conditions and its potential role in cancer progression. It also highlights novel therapeutic drugs and drug targets within the pathway and discusses the implications for treatment strategies and prognosis in liver cancer.